Australia - English - Department of Health (Therapeutic Goods Administration)

visdon pty ltd - camellia sinensis,docosahexaenoic acid (dha)-rich oil derived from microalgae schizochytrium sp.,ginkgo biloba,soy phosphatidylserine-enriched soy lecithin powder -

United States - English - NLM (National Library of Medicine)

clinimmune labs, university of colorado blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 30 ml - hpc (hematopoietic progenitor cells), cord blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. hpc, cord blood is contraindicated in patients with known hypersensitivity to dimethyl sulfoxide (dmso), dextran 40 or plasma proteins. [see description (11) and dosage and administration (2.2)] pregnancy category c. animal reproduction studies have not been conducted with hpc, cord

Bangladesh - English - DGDA (Directorate General of Drug Administration)

nipro jmi company ltd. - blood tubing set for hemodialysis - blood tubing set - 1 size

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 41.7 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; triacetin; allura red ac aluminium lake; indigo carmine aluminium lake; iron oxide red - blooms the chemist rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: blooms the chemist rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). blooms the chemist rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: blooms the chemist rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with blooms the chemist rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 20.8 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; triacetin; allura red ac aluminium lake; indigo carmine aluminium lake; iron oxide red - blooms the chemist rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: blooms the chemist rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). blooms the chemist rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: blooms the chemist rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with blooms the chemist rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; lactose monohydrate; crospovidone; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; triacetin; allura red ac aluminium lake; indigo carmine aluminium lake; iron oxide red - blooms the chemist rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: blooms the chemist rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). blooms the chemist rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: blooms the chemist rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with blooms the chemist rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 5.2 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; crospovidone; lactose monohydrate; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; triacetin; quinoline yellow aluminium lake; indigo carmine aluminium lake; iron oxide yellow - blooms the chemist rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: blooms the chemist rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). blooms the chemist rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: blooms the chemist rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with blooms the chemist rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

United States - English - NLM (National Library of Medicine)

lifesouth community blood centers, inc. - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - cordcyte, hpc (hematopoietic progenitor cell), cord blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. pregnancy category c. animal reproduction studies have not been conducted with cordcyte. it is also not known whether cordcyte can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st

United States - English - NLM (National Library of Medicine)

ssm cardinal glennon children's medical center st. louis cord blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 35 ml - allocord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none pregnancy category c. animal reproduction studies have not been conducted with allocord. it is also not known whether allocord can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st

United States - English - NLM (National Library of Medicine)

new york blood center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - hemacord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none pregnancy category c. animal reproduction studies have not been conducted with hemacord. it is also not known whether hemacord can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st